Matthew Brams - Jun 11, 2024 Form 4 Insider Report for Cingulate Inc. (CING)

Role
EVP and Chief Medical Officer
Signature
/s/ Shane J. Schaffer, Attorney-in-Fact
Stock symbol
CING
Transactions as of
Jun 11, 2024
Transactions value $
$0
Form type
4
Date filed
6/13/2024, 07:59 PM
Previous filing
Apr 1, 2024
Next filing
Jul 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CING Stock Option (right to Buy) Award $0 +63.3K $0.00 63.3K Jun 11, 2024 Common Stock 63.3K $1.18 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024.
F2 The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares in substantially equal monthly installments over the 30-month period following the initial vesting date.